Expertos Invitados





LA HIDROXICLOROQUINA ES DE GRAN UTILIDAD EN EL TRATAMIENTO DEL LUPUS ERITEMATOSO SISTEMICO

(especial para SIIC © Derechos reservados)
La hidroxicloroquina es un fármaco fundamental en el tratamiento del lupus eritematoso sistémico, no sólo por su efecto inmunomodulador e inmunusupresor, sino por otras propiedades pleoitrópicas (metabólicas y antitrombóticas). Es un fármaco seguro incluso durante el embarazo y la lactancia.
jimenezalonso9.jpg Autor:
Juan Jiménez alonso
Columnista Experto de SIIC

Institución:
Unidad de Enfermedades Autoinmunes Sistémicas. Servicio de Medicina Interna. Hospital Universitario Virgen de las Nieves

Artículos publicados por Juan Jiménez alonso
Coautor
José Mario Sabio* 
Doctor en Medicina, Unidad de Enfermedades Autoinmunes Sistémicas. Hospital Universitario Virgen de las Nieves, Granada, España*
Recepción del artículo
14 de Julio, 2006 		Aprobación
24 de Agosto, 2006
Primera edición
31 de Octubre, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

LA HIDROXICLOROQUINA ES DE GRAN UTILIDAD EN EL TRATAMIENTO DEL LUPUS ERITEMATOSO SISTEMICO

Resumen
La utilidad de la hidroxicloroquina en el tratamiento del lupus eritematoso sistémico está ampliamente demostrada. Es un fármaco seguro (incluso durante el embarazo y la lactancia), bien tolerado y económico. La retinopatía asociada a su uso es el único efecto adverso realmente peligroso por cuanto puede provocar ceguera irreversible, que puede evitarse mediante un adecuad control oftalmológico. Existen suficientes datos que respaldan el notable efecto que tiene la hidroxicloroquina sobre el control de la actividad de la enfermedad. También hay evidencias que sugieren que disminuye el daño acumulado en los pacientes lúpicos y podría aumentar su supervivencia. Las propiedades de la hidroxicloroquina parecen ir más allá de su efecto inmumodulador e inmunosupresor. Así, tiene efectos beneficiosos sobre el metabolismo lipídico y glucémico y efectos antitrombóticos que podrían contribuir a prevenir la aterosclerosis.

Palabras clave
Hidroxicloroquina, antipalúdicos, lupus eritematoso sistémico


Artículo completo
(castellano)
Extensión:  +/-6.28 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

HYDROXYCHLOROQUINE IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract
The positive effects of hydroxychloroquine in treating systemic lupus erythematosus is well known. Hydroxychloroquine is a well tolerated and safe drug even during pregnancy and breast feeding, and it has a low cost. Retinopathy is the most serious side-effect associated with its use since irreversible blindness can occur; therefore, an appropriate monitoring of the eye by an ophthalmologist becomes essential. The remarkable effectiveness of hydroxychloroquine to control disease activity has been demonstrated; and there is also evidence suggesting that this drug contributes to prevent damage accrual and to improve survival in lupus patients. Besides the immunomodulating and immunosuppressant properties of hydroxychloroquine, it also has beneficial effects on lipid and glucose metabolism as well as antithrombotic effects that could contribute to prevent arteriosclerosis in these patients.

Key words
Hydroxychloroquine, antimalarials, systemic lupus erythematosus

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Reumatología
Relacionadas: Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 6.28 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Juan Jiménez Alonso, Hospital Universitario Virgen de las Nieves, 18012, Avda. Fuerzas Armadas 2. Servicio de Medicina Interna. 9ª Planta, Granada, España
Bibliografía del artículo
1. Payne JF. A postgraduate lecture on lupus erythematosus. Clin J 1894; 4:223-339.
2. Office of the Surgeon General. Circular Letter N 153. The drug treatment of malaria, surpressive and clinical. JAMA 1943; 123: 205-8.
3. Page F. Treatment of lupus erythematosus with mepacrine. Lancet 1951; 2:755-8.
4. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2:323-30.
5. Sabio JM, Jiménez Alonso J. Antipalúdicos en el tratamiento de las enfermedades autoinmunes sistémicas y reumáticas. Med Integral 2003; 41:34-43.
6. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716-9.
7. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983-7.
8. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23(Suppl 1):82-91.
9. Fox RI, Kang IH. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2:S9-S12.
10. Van den Borne BE, Dijkmans BA, De Rooij HH, Le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997; 24:55-60.
11. Jeong JY, Choi JW, Jeon KI, Jue DM. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002; 105:83-91.
12. Furst DE, Lindsley H, Baethge B, y col. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42:357-365.
13. Toubi E, Rosner I, Rozembaum M, Kessel A, Golan TD. The benefit of combining hydroxychloroquine and quinacrine in the treatment of SLE patients. Lupus 2000; 9:92-95.
14. Williams HJ, Egger MJ, Singer JZ, y col. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457-62.
15. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39:1249-54.
16. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243-63.
17. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150-154.
18. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5:237-41.
19. Fessler BJ, Alarcon GS, McGwin G Jr, y col. LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52:1473-80.
20. Ruiz Irastroza G, Egurbide MV, Ibarra S, y col. Effect of antimalarials on long-term survival of patients with systemic lupus erythematosus. Lupus 2005; 14:220.
21. Asanuma Y, Oeser A, Shintani AK, y col. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349:2407-15.
22. Roman MJ, Shanker BA, Davis A, y col. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-406.
23. Esdaile JM, Abrahamowicz M, Grodzicky T, y col. Traditional Framingham risk factors fall to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheuma 2001; 44:2331-7.
24. Svenungsson E, Jensen-Urstad K, Heimburger M, y col. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-93.
25. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48:3159-67.
26. Doria A, Shoenfeld Y, Wu R, y col. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62:1071-7.
27. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 1:S16-S22.
28. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract 2002; 55:209-19.
29. Smith GD, Christensen JR, Rideout JM, Peters TJ. Hepatic processing of insulin. Characterization of differential inhibition by weak bases. Eur J Biochem 1989; 181:287-94.
30. Bevan AP, Kkrook A, Tikerpae J, Seabright PJ, Siddle K, Smith DG. Chloroquine extends the lifetime of the activated insulin receptor complex in endosotes. J Biol Chem 1997; 272:26833-40.
31. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27:2142-5.
32. Borba EF, Bonfa E. Long term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without stereoid therapy.
33. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26:325-30.
34. Pilcher BD. Hydroxychloroquine sulphate in prevention of thromboembolic phenomena in surgical patients. Am Surg 1975; 41:761-6.
35. Erkan D, Yazici Y, Peterson MG, Sammarino L, Lockshin DM. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41:924-9.
36. Ho KT, Ahn CW, Alarcon GS, y col. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44:1303-7.
37. Jiménez Alonso J, Sabio JM, Carrillo Alascio PL, y col. Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions. Rev Clin Esp 2004; 204:588-91.
38. Rynes RI. Side effects of antimalarial therapy. Br J Clin Pract 1987; 41(Suppl 52):42-5.
39. Jiménez Alonso J, Tercedor J, Reche I. Antimalarial drugs and pruritus in patients with lupus erythematosus. Acta Derm Venereol 2000; 80:458.
40. Jiménez Alonso J, Tercedor J, Jáimez L, García Lora E. Antimalarials drugs-induced aquagenic-type pruritus in patients with lupus. Arthrtis Rheum 1998; 41:744-5.
41. Reche Molina I, Jiménez Alonso J, Pérez Alvarez AF, y col. Pruritus in patients with lupus: interrelations with antimalarial drugs and skin types. Lupus 2001; 10(suppl1):S101.
42. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40:1482-6.
43. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J 1992; 85:274-9.
44. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109:1377-82.
45. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12:692-4.
46. Warner AE. Early hydroxychloroquine macular toxicity. Arthritis Rheum 2001; 44:1959-1961.
47. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 2002; 37:325-8, 331-4.
48. Alarcon GS. How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? Arthritis Rheum 2002; 46:561.
49. Ruiz Irastorza G, Lima F, Alves J, y col. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35:133-8.
50. Cortés Hernández J, Ordi Ros J, Paredes F, Casellas M, Castillo F, Vilardell Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002; 41:643-50.
51. Costedoat-Chalumeau N, Amoura Z, Duhaut P, y col. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48:3207-11.
52. Levy RA, Vilela VS, Cataldo MJ, y col. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10:401-4.
53. Clowse ME, Magder LS, Petri M. The effect of hydroxychloroquine in pregnancy outcomes and disease activity in lupus patients. Arthritis Rheum 2004; 50:S689-S690.
54. Motta M, Tincani A, Faden D, y col. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005; 25:86-9.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008